IH11 - From Digital Divide to AI Advantage: The 5 Strategic Imperatives Transforming Clinical Trial Operations in 2026
Information
Clinical trials reach a critical turning point in 2026. While AI experimentation accelerates across pharma, a significant gap widens between Leaders and organizations still constrained by paper workflows.
This 25-minute session reveals what separates high-performing organizations: Leaders achieve faster startup times and measurable ROI by treating technology as a strategic advantage, while others struggle with manual processes.
Discover the five strategic imperatives driving transformation: crossing the digital divide, implementing flexible digital mandates, preparing for emerging site technologies, experimenting with AI, and investing in persistent intelligence. Learn how 42% of sites now own eRegulatory systems—creating the foundation for predictive operations that transform reactive monitoring.
We'll explore AI adoption patterns in document review, contracting, and risk detection, and demonstrate how Leaders use connected workflows to unlock AI's potential while paper-dependent organizations face growing barriers.
Walk away with actionable strategies to advance your organization from reactive oversight to predictive operations, positioning your trials for the intelligence-driven future where execution becomes observable and compounds with every study.
